Long-Term Adalimumab is Safe and Achieves Disease Control in Children with Advanced and Refractory JIA

Article Information

DOI 
http://dx.doi.org/10.1177/155989771417004
Published By 
SAGE Publications
Print ISSN 
1559-8977
Online ISSN 
2155-756X
Copyright & Usage 
© 2014 MD Conference Express®

Author Information

  1. Jenny Powers
  1. Gerd Horneff, MD
    1. Asklepios Klinik Sankt Augustin, Sankt Augustin, Germany
View Full Text

Article usage

AbstractFullPDF
Apr 2015500
May 2015200
Jun 2015400
Aug 20151411
Sep 2015500
Oct 2015332
Total3343

Note: Article usage statistics are calculated and reported monthly.

Cited By...

  • No citing articles found.
Back to top

Tools

View Full Page PDF
Citation Tools
Email
Long-Term Adalimumab is Safe and Achieves Disease Control in Children with Advanced and Refractory JIA
Permalink: Copy
Linkedin Share Button del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo StumbleUpon logo

Table of contents

Cited By...

  • No citing articles found.

Keywords

Arthritis
Rheumatology Clinical Trials
Rheumatological Autoimmune Disorders
Rheumatology